Recombinant Human FGF basic/FGF2/bFGF, 145 aa TC Grade, CF

Recombinant human FGF basic/FGF2/bFGF, 145 aa TC Grade (Catalog # 4114-TC) has a molecular weight (MW) of 17.2 kDa as analyzed by SEC-MALS, suggesting that this protein is a monomer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).

JOY6 human iPSCs were cultured in media containing Cultrex™ Stem Cell Qualified RGF BME (3434-010-02) and N21-MAX Insulin Free Media Supplement (AR010) along with Recombinant Human Activin A on day 0, Recombinant Human FGF-basic (Catalog # 4114-TC), Recombinant Human BMP-4, and CHIR99021 (4423) on days 1-5, and Recombinant Human Dkk-1 (5439-DK) on days 5-7 to induce cardiomyocyte differentiation. Cells were then cultured in media supplemented with N21-MAX Insulin Free Media Supplement (AR010) on days 7-12 and media supplemented with N21-MAX Media Supplement (AR008) from day 12 and beyond. Cells were fixed and stained for stage-specific markers at select time points during the procedure. The pluripotency marker Oct-4 was detected using a Mouse Anti-Human Oct-4A Monoclonal Antibody (MAB17591). The mesoderm marker, Snail is expressed intermediately during differentiation (Day 1). It was detected using a Goat Anti-Human Snail Polyclonal Antibody (AF3639). The cardiomyocyte markers NKX2.5 and Troponin T are not present in cells during early (Day 0) and intermediate (Day1) differentiation and become more highly expressed during the later stages of differentiation (Day 7, Day 30). NKX2.5 was detected using a Goat Anti-Human NKX2.5 Polyclonal Antibody (AF2444) and Troponin T was detected using a Mouse Anti-Human Cardiac Troponin T Monoclonal Antibody (MAB1874). Snail and NKX2.5 primary antibodies were visualized with a NorthernLights™ 557-conjugated Donkey Anti-Goat IgG Secondary Antibody (NL001). Oct-4 and Troponin T were visualized with a NorthernLights 557-conjugated Donkey Anti-Mouse IgG Secondary Antibody (NL007).

JOY6 human induced pluripotent stem cells (iPSCs) were differentiated into cardiomyocytes in media containing Cultrex™ Stem Cell Qualified Reduced Growth Factor Basement Membrane Extract (3434-010-02) and N21-MAX Insulin Free Media Supplement (AR010) along with Recombinant Human Activin A on day 0, Recombinant Human FGF-basic (Catalog # 4114-TC), Recombinant Human BMP-4, and CHIR99021 (4423) on days 1-5, and Recombinant Human Dkk-1 (5439-DK) on days 5-7. Following culture in media supplemented with N21-MAX Insulin Free Media Supplement (AR010) on days 7-12 and media supplemented with N21-MAX Media Supplement (AR008) from day 12 and beyond, cells were fixed and stained for the atrial-specific marker, MLC2a, and the ventricle-specific marker, MYH7 using a Rabbit Anti-Human MYH7 Monoclonal Antibody (MAB90961).

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human FGF basic/FGF2/bFGF, 145 aa TC Grade, CF Summary

• Additional Information: Analyzed by SEC-MALS
• Details of Functionality: The protein is used at 20 ng/mL to support a 100-fold expansion of rat cortical neural stem cells or mouse cortical stem cells over 3 passages. Cells were cultured in N2 plus medium and supplemented with FGF basic every day. Measured in a cell proliferation assay using NR6R-3T3 mouse fibroblast cells. Raines, E.W. et al. (1985) Methods Enzymol. 109:749. The ED 50 for this effect is 0.3-3 ng/mL.
• Source: E. coli-derived human FGF basic/FGF2/bFGF protein Ala144-Ser288
• Accession #: NP_001997
• N-terminal Sequence: Ala144
• Protein/Peptide Type: Recombinant Proteins
• Gene: FGF2
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 16 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris-HCl and NaCl.
• Reconstitution Instructions: Reconstitute at 0.5-1.0 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human FGF basic/FGF2/bFGF, 145 aa TC Grade, CF

• basic fibroblast growth factor bFGF
• Basic fibroblast growth factor
• bFGF
• FGF basic
• FGF2
• FGF-2
• FGFBprostatropin
• fibroblast growth factor 2 (basic)
• HBGF-2
• heparin-binding growth factor 2
• Prostatropin

Background

FGF basic (also known as FGF2 and HBGF-2) is an 18-34 kDa, heparin-binding member of the FGF superfamily of molecules (1-3). Superfamily members are characterized by the presence of a centrally placed beta -trefoil structure. FGF acidic (FGF1) and FGF basic (FGF2) were the first two identified FGFs, and the designations acidic and basic refer to their relative isoelectric points. Human FGF basic is 288 amino acids (aa) in length. There are multiple start sites, four of which utilize atypical CUG codons, and one that initiates at an AUG start site (4-6). The four CUG start sites generate high molecular weight (HMW) FGF basic. There is a 34 kDa, 288 aa form, a 24 kDa, 210 aa form, a 22.5 kDa, 201 aa form, and a 22 kDa, 196 aa form. All are retained intracellularly, undergo extensive methylation, and possess one or more nuclear localization signals (NLS) (7-9). The AUG initiating form is 18 kDa and 155 aa in length. There is no signal sequence (ss). It is, however, secreted directly through the plasma membrane via a mechanism that appears to be dependent upon tertiary structure (10). In place of a ss, there is purportedly a 9 aa N-terminal prosegment that precedes a 146 aa mature segment (11). Early isolations of 18 kDa bovine FGF basic yielded 146 aa molecules, an effect attributed to the presence of acid proteases (12). The molecule contains a heparin-binding site (aa residues 128-144), and undergoes phosphorylation at Ser117 (13). There is also an ill-defined C-terminal NLS that may be more “functional” (or 3-dimensional) than structural (7). Human 146 aa FGF basic is 97% aa identical to mouse FGF basic (14).

1. Sorenson, V. et al. (2006) BioEssays 28:504.
2. Kardami, E. et al. (2004) Cardiovasc. Res. 63:458.
3. Nugent, M.A. and R.V. Lozzo (2000) Int. J. Biochem. Cell Biol. 32:115.
4. Abraham, J.A. et al. (1986) EMBO J. 5:2523.
5. Prats, H. et al. (1989) Proc. Natl. Acad. Sci. USA 86:1836.
6. Arnaud, E. et al. (1999) Mol. Cell. Biol. 19:505.
7. Foletti, A. et al. (2003) Cell. Mol. Life Sci. 60:2254.
8. Arese, M. et al. (1999) Mol. Biol. Cell 10:1429.
9. Pintucci, G. et al. (1996) Mol. Biol. Cell 7:1249.
10. Nickel, W. (2005) Traffic 6:607.
11. SwissProt # P09038.
12. Klagsbrun, M. et al. (1987) Proc. Natl. Acad. Sci. USA 84:1839.
13. Bailly, K. et al. (2000) FASEB J. 14:333.
14. Hebert, J.M. et al. (1990) Dev. Biol. 138:454.

Publications for FGF basic/FGF2/bFGF (4114-TC)(31)

Publications using 4114-TC

• Kim, S;Jung, BK;Kim, J;Jeon, JH;Kim, M;Jang, SH;Kim, CS;Jang, H; Anticancer effect of the oncolytic Newcastle disease virus harboring the PTEN gene on glioblastoma Oncology letters 2025-01-01 [PMID: 39492938] (Bioassay, Human)
• Delila, L;Nebie, O;Le, NTN;Timmerman, K;Lee, DY;Wu, YW;Chou, ML;Buée, L;Chou, SY;Blum, D;Devos, D;Burnouf, T; Neuroprotective effects of intranasal extracellular vesicles from human platelet concentrates supernatants in traumatic brain injury and Parkinson's disease models Journal of biomedical science 2024-09-05 [PMID: 39237980] (Bioassay, Human)
• Thangaraj, JL;Coffey, M;Lopez, E;Kaufman, DS; Disruption of TGF-? signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells Cell stem cell 2024-07-01 [PMID: 38986609] (Bioassay, Human)
• Lin, P;Chen, W;Long, Z;Yu, J;Yang, J;Xia, Z;Wu, Q;Min, X;Tang, J;Cui, Y;Liu, F;Wang, C;Zheng, J;Li, W;Rich, JN;Li, L;Xie, Q; RBBP6 maintains glioblastoma stem cells through CPSF3-dependent alternative polyadenylation Cell discovery 2024-03-19 [PMID: 38503731] (Bioassay, Xenograft)
• Yin, J;Seo, Y;Rhim, J;Jin, X;Kim, TH;Kim, SS;Hong, JH;Gwak, HS;Yoo, H;Park, JB;Kim, JH; Crosstalk between PARN and EGFR-STAT3 Signaling Facilitates Self-Renewal and Proliferation of Glioblastoma Stem Cells Cancer research 2023-09-25 [PMID: 37747775] (Bioassay, Human)
• Tian, JL;Huang, CW;Eslami, F;Mannino, MP;Mai, RL;Hart, GW; Regulation of Primary Cilium Length by O-GlcNAc during Neuronal Development in a Human Neuron Model Cells 2023-05-31 [PMID: 37296641] (Cell Culture, Human)
• Yuan, H;Wu, X;Wu, Q;Chatoff, A;Megill, E;Gao, J;Huang, T;Duan, T;Yang, K;Jin, C;Yuan, F;Wang, S;Zhao, L;Zinn, PO;Abdullah, KG;Zhao, Y;Snyder, NW;Rich, JN; Lysine catabolism reprograms tumour immunity through histone crotonylation Nature 2023-05-17 [PMID: 37198486] (Bioassay, Human)
• E Cuevas, A Guzman, SM Burks, A Ramirez-Le, SF Ali, SZ Imam Autophagy and protein aggregation as a mechanism of dopaminergic degeneration in a primary human dopaminergic neuronal model Toxicology reports, 2022-04-01;9(0):806-813. 2022-04-01 [PMID: 36518412] (Bioassay, Human)
• EJ Kim, JY Kim, SO Kim, N Hong, SH Choi, MG Park, J Jang, SW Ham, S Seo, SY Lee, K Lee, HJ Jeong, SJ Kim, S Jeong, K Min, SC Kim, X Jin, SH Kim, SH Kim, H Kim The oncogenic JAG1 intracellular domain is a transcriptional cofactor that acts in concert with DDX17/SMAD3/TGIF2 Cell Reports, 2022-11-22;41(8):111626. 2022-11-22 [PMID: 36417870] (Bioassay, Human, Transgenic Mouse)
• L Mahoney-Sa, H Bouchaoui, I Boussaad, A Jonneaux, K Timmerman, O Berdeaux, S Ayton, R Krüger, JA Duce, D Devos, JC Devedjian Alpha synuclein determines ferroptosis sensitivity in dopaminergic neurons via modulation of ether-phospholipid membrane composition Cell Reports, 2022-08-23;40(8):111231. 2022-08-23 [PMID: 36001957] (Bioassay, Human)
• D Sardar, HC Chen, A Reyes, S Varadharaj, A Jain, C Mohila, R Curry, B Lozzi, K Rajendran, A Cervantes, K Yu, A Jalali, G Rao, SC Mack, B Deneen Sox9 directs divergent epigenomic states in brain tumor subtypes Oncogene, 2022-07-15;119(29):e2202015119. 2022-07-15 [PMID: 35858326] (Bioassay, Mouse)
• Elena Fdez, Jesús Madero-Pérez, Antonio J. Lara Ordóñez, Yahaira Naaldijk, Rachel Fasiczka, Ana Aiastui et al. Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacement iScience 2022-06-17 [PMID: 35721463] (Bioassay, Human)
• M Kobayashi, M Kobayashi, J Odajima, K Shioda, YS Hwang, K Sasaki, P Chatterjee, C Kramme, RE Kohman, GM Church, AR Loehr, RS Weiss, H Jüppner, JJ Gell, CC Lau, T Shioda Expanding homogeneous culture of human primordial germ cell-like cells maintaining germline features without serum or feeder layers Stem Cell Reports, 2022-02-10;0(0):. 2022-02-10 [PMID: 35148847] (Bioassay, Human)
• AN Cho, Y Jin, Y An, J Kim, YS Choi, JS Lee, J Kim, WY Choi, DJ Koo, W Yu, GE Chang, DY Kim, SH Jo, J Kim, SY Kim, YG Kim, JY Kim, N Choi, E Cheong, YJ Kim, HS Je, HC Kang, SW Cho Microfluidic device with brain extracellular matrix promotes structural and functional maturation of human brain organoids Nature Communications, 2021-08-05;12(1):4730. 2021-08-05 [PMID: 34354063] (Bioassay, Human)
• SG Kim, S Lee, Y Kim, J Park, D Woo, D Kim, Y Li, W Shin, H Kang, C Yook, M Lee, K Kim, JD Roh, J Ryu, H Jung, SM Um, E Yang, H Kim, J Han, WD Heo, E Kim Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons Nature Communications, 2021-05-11;12(1):2695. 2021-05-11 [PMID: 33976205] (Bioassay, Human)
• L Jerby-Arno, C Neftel, ME Shore, HR Weisman, ND Mathewson, MJ McBride, B Haas, B Izar, A Volorio, G Boulay, L Cironi, AR Richman, LC Broye, JM Gurski, CC Luo, R Mylvaganam, L Nguyen, S Mei, JC Melms, C Georgescu, O Cohen, JE Buendia-Bu, A Segerstolp, M Sud, MS Cuoco, D Labes, S Gritsch, DR Zollinger, N Ortogero, JM Beechem, G Petur Niel, I Chebib, T Nguyen-Ngo, M Montemurro, GM Cote, E Choy, I Letovanec, S Cherix, N Wagle, PK Sorger, AB Haynes, JT Mullen, I Stamenkovi, MN Rivera, C Kadoch, KW Wucherpfen, O Rozenblatt, ML Suvà, N Riggi, A Regev Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma Nature Medicine, 2021-01-25;0(0):. 2021-01-25 [PMID: 33495604] (Bioassay, Human)
• M Bae, JD Roh, Y Kim, SS Kim, HM Han, E Yang, H Kang, S Lee, JY Kim, R Kang, H Jung, T Yoo, H Kim, D Kim, H Oh, S Han, D Kim, J Han, YC Bae, H Kim, S Ahn, AM Chan, D Lee, JW Kim, E Kim SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function Embo Molecular Medicine, 2021-01-11;0(0):e12632. 2021-01-11 [PMID: 33428810] (Bioassay, Human)
• W Tao, A Zhang, K Zhai, Z Huang, H Huang, W Zhou, Q Huang, X Fang, BC Prager, X Wang, Q Wu, AE Sloan, MS Ahluwalia, JD Lathia, JS Yu, JN Rich, S Bao SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells EMBO Mol Med, 2020-10-30;0(0):e12291. 2020-10-30 [PMID: 33124191] (Bioassay, Human)
• EAA Obara, D Aguilar-Mo, RD Rasmussen, A Frias, K Vitting-Se, YC Lim, KJ Elbæk, H Pedersen, L Vardouli, KE Jensen, J Skjoth-Ras, J Brennum, L Tuckova, R Strauss, C Dinant, J Bartek, P Hamerlik SPT6-driven error-free DNA repair safeguards genomic stability of glioblastoma cancer stem-like cells Nat Commun, 2020-09-18;11(1):4709. 2020-09-18 [PMID: 32948765] (Bioassay, Human)
• L Zhang, J Avery, A Yin, AM Singh, TS Cliff, H Yin, S Dalton Generation of Functional Brown Adipocytes from Human Pluripotent Stem Cells via Progression through a Paraxial Mesoderm State Cell Stem Cell, 2020-08-11;0(0):. 2020-08-11 [PMID: 32783886] (Bioassay, Human)
• H Zhu, RH Blum, D Bernareggi, EH Ask, Z Wu, HJ Hoel, Z Meng, C Wu, KL Guan, KJ Malmberg, DS Kaufman Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In�Vivo Persistence and Enhances Anti-tumor Activity Cell Stem Cell, 2020-06-11;0(0):. 2020-06-11 [PMID: 32531207] (Bioassay, Human)
• AM Singh, L Zhang, J Avery, A Yin, Y Du, H Wang, Z Li, H Fu, H Yin, S Dalton Human beige adipocytes for drug discovery and cell therapy in metabolic diseases Nat Commun, 2020-06-02;11(1):2758. 2020-06-02 [PMID: 32488069] (Bioassay, Human)
• N Micali, SK Kim, M Diaz-Busta, G Stein-O'Br, S Seo, JH Shin, BG Rash, S Ma, Y Wang, NA Olivares, JI Arellano, KR Maynard, EJ Fertig, AJ Cross, RW Bürli, NJ Brandon, DR Weinberger, JG Chenoweth, DJ Hoeppner, N Sestan, P Rakic, C Colantuoni, RD McKay Variation of Human Neural Stem Cells Generating Organizer States In�Vitro before Committing to Cortical Excitatory or Inhibitory Neuronal Fates Cell Rep, 2020-05-05;31(5):107599. 2020-05-05 [PMID: 32375049] (Cell Culture, Mouse)
• J Cholewa-Wa, R Shah, S Webb, K Chhatbar, B Ramsahoye, O Pusch, M Yu, P Greulich, B Waclaw, AP Bird Quantitative modelling predicts the impact of DNA methylation on RNA polymerase II traffic Proc. Natl. Acad. Sci. U.S.A., 2019-07-09;116(30):14995-15000. 2019-07-09 [PMID: 31289233] (Bioassay, Human)
• JA Bernatchez, M Coste, S Beck, GA Wells, LA Luna, AE Clark, Z Zhu, D Hecht, JN Rich, CD Sohl, BW Purse, JL Siqueira-N Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells Viruses, 2019-04-20;11(4):. 2019-04-20 [PMID: 31010044] (Bioassay, Human)
• S Beck, Z Zhu, MF Oliveira, DM Smith, JN Rich, JA Bernatchez, JL Siqueira-N Mechanism of Action of Methotrexate Against Zika Virus Viruses, 2019-04-10;11(4):. 2019-04-10 [PMID: 30974762] (Cell Culture, Human)
• T Colunga, M Hayworth, S Kre beta , DM Reynolds, L Chen, KL Nazor, J Baur, AM Singh, JF Loring, M Metzger, S Dalton Human Pluripotent Stem Cell-Derived Multipotent Vascular Progenitors of the Mesothelium Lineage Have Utility in Tissue Engineering and Repair Cell Rep, 2019-03-05;26(10):2566-2579.e10. 2019-03-05 [PMID: 30840882] (Bioassay, Human)
• EK Kim, JH Cho, E Kim, YJ Kim Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth PLoS ONE, 2017-07-14;12(7):e0181183. 2017-07-14 [PMID: 28708871] (Bioassay, Human)
• Kristen M Bullard-Fe The FDA-approved drug sofosbuvir inhibits Zika virus infection Antiviral Res, 2016-11-27;137(0):134-140. 2016-11-27 [PMID: 27902933] (Bioassay, Human)
• Adepoju A, Micali N, Ogawa K, Hoeppner D, McKay R FGF2 and insulin signaling converge to regulate cyclin D expression in multipotent neural stem cells. Stem Cells, 2014-03-01;32(3):770-8. 2014-03-01 [PMID: 24155149] (Bioassay, Mouse)
• West FD, Machacek DW, Boyd NL, Pandiyan K, Robbins KR, Stice SL Enrichment and differentiation of human germ-like cells mediated by feeder cells and basic fibroblast growth factor signaling. Stem Cells, 2008-08-21;26(11):2768-76. 2008-08-21 [PMID: 18719225] (Bioassay, Human)

FAQs for FGF basic/FGF2/bFGF (4114-TC). (Showing 1 - 1 of 1 FAQs).

1. I am looking for an ovine antibody for bFGF and PDGF-AB and ELISA Kits for both. It is for a research work on meniscus healing in sheep. Do you have anything suitable? How is the homology with sheep? Is it ever tested and/or published in papers?
   • Unfortunately, most of the products you are interested in have not yet been tested in sheep, but this should not be a problem, due to sequence homology, and our Innovators Reward Program. In terms of an antibody for bFGF, also called FGF-2, we have several antibodies that are validated to detect the bovine protein, which is almost identical to that from sheep (99% homology). We only have FGF2 ELISA kits that have been tested with human or mouse. Mouse FGF-2 has 94% homology with sheep; human has 98% homology for most of its sequence, but also has an additional stretch of amino acids that is not present in the sheep protein. I therefore think that the mouse kit would be most suitable, just in case the human kit targets the region of the human protein not present in mouse. We sell antibodies to PDGF-A or PDGF-B rather than PDGF-AB. We don't have any PDGF-A antibodies that have been tested in sheep but there are several options you may find of interest. There isn't a sheep PDGFA sequence in UniProt, so I can't comment on how similar it is to the PDGFA from other species. Nevertheless, our NBP1-52533 PDGFB antibody has been shown to work in sheep. We sell two PDGF-AB ELISA kits , but these are for human and rat. I'm not sure how well these would work with sheep. Note that if you test a product with a species (or application) that it has not yet been validated in, you are eligible for our Innovator's Reward: Novus would provide you a 50% refund on the purchased product as well as a 50% discount on a future product of equal or lesser value. You would email innovators@novusbio.com to apply for your award, and we

Bioinformatics

• Gene Symbol: FGF2
• Uniprot:
  • NP_001997()